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Abstract
Background: age-specific mortality reduction has been accompanied by a decrease in the prevalence of some diseases and
an increase in others. Whether populations are becoming ‘healthier’ depends on which aspect of health is being considered.
Frailty has been proposed as an integrative measure to quantify health status.
Objective: to investigate changes in the near-term lethality of frailty before and after a 20-year interval using the frailty
index (FI), a summary of age-related health deficit accumulation.
Design: baseline data from the Cognitive Function and Ageing Studies (CFAS) in 1991 (n = 7,635) and 2011 (n = 7,762).
Setting: three geographically distinct UK centres (Newcastle, Cambridgeshire and Nottingham).
Subjects: individuals aged 65 and over (both institutionalised and community-living).
Methods: a 30-item frailty score was used, which includes morbidities, risk factors and subjective measures of disability.
Missing items were imputed using multiple imputations by chained equations. Binomial regression was used to investigate
the relationship between frailty, age, sex and cohort. Two-year mortality was modelled using logistic regression.
Results: mean frailty was slightly higher in CFAS II (0.19, 95% confidence interval (CI): 0.19–0.20) than CFAS I (0.18,
95% CI: 0.17–0.18). Two-year mortality in CFAS I was higher than in CFAS II (odds ratio (OR) = 1.16, 95% CI:
1.03–1.30). The association between frailty and 2-year mortality was non-linear with an OR of ~1.6 for each 0.10 increment
in the FI.
Conclusions: the relationship between frailty and mortality did not significantly differ across the studies. Severe frailty as an
indicator of mortality is shown to be a stable construct.
Keywords: frailty, mortality, frailty index, Cognitive Function and Ageing Study (CFAS), older people
Recent advancements in health have led to reductions in
mortality and increased life expectancy in both high- and
low-income countries. Consequently, the prevalence of age-
related chronic diseases, such as diabetes mellitus, ischaemic
heart disease and liver disease, has increased [1, 2]. Even so,
reductions have been observed in cognitive impairment and
functional disability [3]. Deciding whether decreases in mor-
tality are a result of health improvements therefore depends
on which aspect of health is being measured. The relation-
ship between different health conditions and mortality is
complex, so characterising a population’s health in terms of
each condition is challenging. As an integrative concept,
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frailty in the clinical sense brings together different health
components, including disability and cognition [4].
Frailty is characterised as the loss of reserves leading to
a state of increased vulnerability for adverse health out-
comes [4–8]. One approach to measuring frailty is by an
index of ‘deficit accumulation’ [5, 9]. The frailty index (FI)
can be a better predictor of mortality than chronological
age [10–12], and relative to other frailty instruments, has a
high predictive validity for a number of negative outcomes
[13, 14].
Frailty measures are being increasingly adopted within
clinical settings, including primary and social care. In the
UK, the electronic frailty index (eFI) consisting of routinely
collected primary care electronic health record data has
been validated against mortality, hospitalisation and nursing
home admission using data from 931,541 patients [15]. In
general, the FI is a useful indicator of needs, which include
hospital discharge, institutionalisation or continuing care
[16]. Despite the established association between frailty and
adverse outcomes, as well as the increase in health service
use [17], quality of care for those with high frailty scores is
often inadequate with unmet healthcare needs [18, 19]. The
FI has a policy relevance which needs to be underpinned by
thorough understanding of its performance across time.
Large longitudinal studies have studied frailty and its
association with survival up to 15 years [20–22]. Most
frailty research has investigated long-term survival and mor-
tality over extended periods [23]. Clinical utility for the
index is likely to be more useful over shorter periods, but
limited research has examined how the relationship between
frailty and short-term mortality may have changed [23].
Using a 30-item FI based on variables collected in the
Medical Research Council Cognitive Function and Ageing
Study, we examine whether frailty provides a stable indica-
tor of mortality risk across decades, therefore validating its
status as a robust marker of need. Alternatively, if the per-
formance of frailty changes this may be because the vari-
ables making it up now have different implications.
Methods
Study design
The Cognitive Function and Ageing Studies (CFAS) are
population-based longitudinal studies of ageing which
examine risk factors and health outcomes in the older UK
population. Recruitment for CFAS I began in 1991 and
CFAS II was initiated in 2008. Full details of the methods
have been published elsewhere [24, 25] and are explained in
brief here.
In three geographical sites (two urban, Newcastle and
Nottingham, and one rural, Cambridgeshire), using the
same sampling methods (National Health Service Primary
Care lists), random samples of people aged 65 and over
were drawn (CFAS I, n = 7,635 and CFAS II, n = 7,762 at
baseline). All participants were flagged at the Office for
National Statistics for routine death notification to deter-
mine mortality up to 2 years from initial interview.
Construction of the CFAS frailty index
The CFAS-FI is composed of 30 items—or deficits—and
subject to best practice in determining the FI, these items
accumulate with age, influence vulnerability to adverse out-
comes, and are neither very rare nor very common in the
population [9]. Each deficit is weighted equally and is
scored based on its presence or absence. The FI is
expressed as a proportion of deficits present out of the total
answered. The deficits (Appendix A in the Supplementary
data, available at Age and Ageing online), were measured
identically in CFAS I and II and include items across a
range of health domains.
Missing frailty data were partly completed using inform-
ant assessment interviews at baseline, from relatives or
friends. The informant’s response was only taken into
account for those with missing items, and where informants
were certain about the subject’s condition.
Statistical analysis methods
Binomial regression was used to investigate the relationship
between frailty, age and sex initially stratified by, and then
adjusted for, cohort. To investigate the relationship between
frailty and mortality risk, a logistic regression analysis with
death at 2 years was undertaken, adjusting for age, sex and
cohort. To model a non-linear association between frailty
and mortality, a quadratic term was included in addition to
the main effect of frailty. The presence of any potential
interactions between frailty, study, age and sex was tested.
Receiver operating characteristic curve analysis was used to
calculate the area under the curve (AUC) for the mortality
models. Sensitivity analyses were undertaken including (a)
Cox regression, taking into account time to death up to 2
years, (b) removing three items (medicated hypertension,
diabetes and thyroid problems), which are now more readily
diagnosed and (c) removing two items (cognitive impair-
ment and depression), which are markers of non-
participation.
Non-response weights, calculated using inverse probabil-
ity weighting, were used throughout to adjust for initial
non-response (20% in CFAS I and 44% in CFAS II) by sex,
age, living in care and deprivation [24]. Missing data in the
FI (8.4% of participants) were investigated initially by
excluding all individuals with missing data (complete-case
analysis), followed by pro-rata calculation for those with
only one missing deficit, together with missing data imput-
ation using chained equations (MICE). Ten iterations were
used to impute missing data. Each frailty item was imputed
separately before calculating the score. Observed hearing
had the fewest missing values (1.0%). Deficits with the
most missing values were difficulty to get on a bus (3.7%)
and self-reported health (3.5%). The regression used for the
imputation adjusted for the response of all other items, as
A. Mousa et al.
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well as age, sex and study. Here, we present the results of the
imputed analysis as the main analysis (results of all methods
are tabulated in Appendix B, in the Supplementary data,
available at Age and Ageing online).
Results
Sample characteristics
Both cohorts included more women than men (CFAS I:
61%, CFAS II: 56%), and by design, the median age in the
population was 75. The submaximal limit to frailty incorp-
orating 99% of the subjects was 0.57 (maximal limit =
0.73) in both studies. Scores on the FI were positively
skewed with a median of 0.13 in CFAS I and 0.17 in CFAS
II (Appendix C in the Supplementary data, available at Age
and Ageing online). Mean frailty was slightly higher in CFAS II
(0.19, 95% confidence interval (CI): 0.19–0.20) than CFAS I
(0.18, 95% CI :0.17–0.18), with a relative increase of 8.4%.
Appendix A, in the Supplementary data, available at Age and
Ageing online gives the crude, unadjusted proportions for
each of the deficits. The highest relative increase across time
was observed for medicated hypertension (24%). Cognitive
impairment and transient ischaemic attack had the highest
relative decrease (7% and 6%, respectively).
Age and sex-specific frailty
In the unadjusted analysis women had higher scores than
men in both studies (Appendix D in the Supplementary
data, available at Age and Ageing online). Both genders had
slightly higher frailty scores (0.5 more deficits on average)
in CFAS II than CFAS I (difference = 0.015, 95% CI:
0.01–0.02). The mean frailty score for men was 0.15 in
CFAS I and 0.16 in CFAS II and for women it was 0.20
and 0.21, respectively. Median frailty indices were lower
because of the skewed distribution (Appendix D in the
Supplementary data, available at Age and Ageing online).
The relationship between the FI and age by study is
shown in Figure 1 and Appendix E in the Supplementary
data, available at Age and Ageing online, which takes into
account gender differences. Women had more deficits than
men (relative risk (RR) = 1.21, 95% CI: 1.18–1.24) and
there was a steady increase in frailty with age (RR = 1.23
for each 5-year increase, 95% CI: 1.22–1.24). There was no
evidence of an interaction effect between age and sex (P =
0.44). When modelling the two studies separately, the rela-
tionship between age and sex on frailty was similar.
Frailty index and mortality
Two-year mortality in CFAS II was significantly lower than
in CFAS I (odds ratio (OR) = 0.86, 95% CI: 0.77–0.97).
Within 2 years, 819 participants (10.7%) died in CFAS I
whereas 643 (8.3%) died in CFAS II. In CFAS I, the
unadjusted odds of dying for men was 1.36 times that of
women (95%CI:1.18–1.58). Death in men declined (from
12.9% in CFAS I to 9.1% in CFAS II) but in women it
remained constant (9.8% vs. 10.0%). Hence, the difference
in 2-year mortality between men and women was no longer
significant in CFAS II (OR = 0.90, 95% CI: 0.76–1.07).
The FI was a significant predictor of mortality after
adjustment for study (Appendix F—Model A in the
Supplementary data, available at Age and Ageing online).
Figure 2 shows 2-year mortality increasing with increasing
frailty. For the less frail, 2-year mortality was similar in
CFAS I and II but for the more frail, mortality decreased in
CFAS II. For instance, the predicted probability of dying
within 2 years for a participant scoring 0.1 on the FI is 1.2%
lower in CFAS II than in CFAS I (4.1% vs. 5.4%, OR =
1.32). However, for a FI of 0.5 (OR = 1.20), the predicted
probability of death within 2 years was 37.0% in CFAS I and
30.7% in CFAS II. Mortality means at high frailty levels were
calculated from a small number of individuals as frailty
scores of over 0.6 were extremely rare (<1% of the sample),
explaining the high variability in observed mortality for high
frailty scores (Figure 2).
The relationship between frailty and mortality was
adjusted for age, sex and study (Appendix F—Model B in
the Supplementary data, available at Age and Ageing online).
The adjusted OR for the FI was ~1.6 for each 0.1 increase
in the FI. The odds of 2-year mortality for men was almost
80% greater than for women (OR = 1.78, 95% CI:
1.56–2.03). For each 5-year increase in age, the odds of
2-year mortality increased by half (OR = 1.52, 95%
CI:1.45–1.59). Accounting for frailty, age and sex, mortality
in CFAS I was considerably higher than CFAS II (OR =
1.48, 95% CI: 1.31–1.67). Interactions were found between
the effects of age and study, and sex and study on mortality.
These were clinically small but statistically significant and
therefore included in the final model for completeness
(Appendix B in the Supplementary data, available at Age
Figure 1. The relationship between age and the frailty in
Cambridgeshire, Newcastle and Nottingham, UK, 1991
(CFAS I) and 2011 (CFAS II). The frailty index is shown as a
proportion of deficits at baseline. The solid and dotted lines
show the predicted frailty as derived from the binomial model.
The symbols denote the observed means of frailty at each age,
calculated from the imputed dataset.
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and Ageing online). The AUC for the imputed analysis was
slightly higher when compared with the AUC for the
complete-case analysis and that including response to 29
items. After adjustment of all variables and significant inter-
actions, the effect of frailty on mortality was higher in the
imputed analysis than using the other methods (Appendix B
in the Supplementary data, available at Age and Ageing online).
The predicted probabilities derived from the final model are
shown in Appendices G and H, in the Supplementary data,
available at Age and Ageing online. In this model, the odds of
2-year mortality were over four times higher (OR = 4.34,
95% CI: 3.23–5.45) in those with a FI of 0.30 compared
with those with a FI of zero (Appendix F—Final model in
the Supplementary data, available at Age and Ageing online).
The age and sex-adjusted relationship of frailty and mor-
tality were also tested in an analysis stratified by study
(Table 1). The difference in fatality of frailty between the
cohorts was not statistically significant (OR for interaction =
1.61, 95% CI: 0.68–3.83, P = 0.28; Table 1), indicating that
the relationship between mortality and frailty has not signifi-
cantly changed over time. In CFAS II, the relationship
between mortality and frailty was non-linear, therefore com-
parisons between each increment of additional frailty
between the studies is influenced by the non-linearity. In
CFAS I, each 0.10 increase in the FI had an OR of 1.57,
but for CFAS II the OR was initially higher (1.72) reducing
to 1.55 with increasing frailty. The FI had a high discrimin-
ation for predicting death up to 2 years, with an AUC of
0.72 in CFAS I and 0.77 for CFAS II (Appendix I in the
Supplementary data, available at Age and Ageing online).
Sensitivity analysis using Cox regression revealed no
change to the conclusions (Appendix J in the
Supplementary data, available at Age and Ageing online).
Removing hypertension, diabetes and thyroid items from
the index resulted in lower frailty indices in CFAS II, which
seem to explain the cohort difference in frailty. Conversely,
removing cognitive impairment and depression from the
index resulted in higher scores in CFAS II. However, no
substantial differences were observed in the mortality mod-
els’ coefficients for either of the sensitivity analyses
(Appendix J in the Supplementary data, available at Age and
Ageing online).
Discussion
Our key findings from this comparison of frailty across two
decades are that, despite a slight increase in the frailty of
the population and a marked decrease in the mortality of
the general population aged 65 and over in three geograph-
ical regions in the UK, the relationship between frailty and
2-year mortality has been relatively stable. This complex
relationship may be, at least partly, accounted for by a
reduction of mortality at lower levels of frailty and
improved diagnosis.
Strengths and weaknesses
One limitation of the study is that frailty does not reflect a
trajectory as it is measured only at one timepoint, with dif-
ferent cohorts providing age-specific cross-sectional asso-
ciations. The use of longitudinal studies to investigate
temporal changes in frailty with respect to adverse out-
comes may help strengthen the conclusions. For example,
in the Canadian National Population Health Survey, ana-
lyses of longitudinal data showed a greater rate of change in
frailty scores over 16 years than was inferred from cross-
sectional data [26]. In addition, response rates were much
lower in CFAS II than CFAS I, a bias partly addressed
Figure 2. Crude 2-year mortality (%) by frailty index in
CFAS I and II. The solid and dotted lines show the predicted
frailty as derived by the logistic regression model and the sym-
bols denote the means of mortality for each frailty score as a
proportion of deficits.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. The relationship between frailty and mortality in
an analysis stratified by study. Separate models were run for
CFAS I and II. Both models included the non-linear effect
of frailty and were adjusted for age and sex
Effect of a 0.1 increase in FI Effect compared to FI = 0
Frailty index
(FI)
Ref. FI Odds ratio (95% CI) Ref. FI Odds ratio (95% CI)
CFAS I
0.1 0 1.57 (1.31, 1.83) 0 1.57 (1.31, 1.83)
0.2 0.1 1.57 (1.41, 1.73) 0 2.47 (1.82, 3.11)
0.3 0.2 1.57 (1.48, 1.66) 0 3.87 (2.69, 5.05)
0.4 0.3 1.57 (1.46, 1.69) 0 6.08 (4.25, 7.92)
0.5 0.4 1.57 (1.37, 1.77) 0 9.55 (6.81, 12.30)
0.6 0.5 1.57 (1.27, 1.87) 0 15.00 (9.91, 20.09)
0.7 0.6 1.57 (1.17, 1.97) 0 23.56 (11.49, 35.63)
CFAS II
0.1 0 1.72 (1.37, 2.07) 0 1.72 (1.37, 2.07)
0.2 0.1 1.69 (1.46, 1.91) 0 2.90 (1.93, 3.87)
0.3 0.2 1.66 (1.53, 1.79) 0 4.81 (2.89, 6.73)
0.4 0.3 1.63 (1.51, 1.75) 0 7.84 (4.66, 11.02)
0.5 0.4 1.60 (1.39, 1.81) 0 12.56 (7.78, 17.34)
0.6 0.5 1.57 (1.26, 1.89) 0 19.77 (12.05, 27.48)
0.7 0.6 1.55 (1.12, 1.97) 0 30.55 (14.55, 46.59)
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by the inverse probability weights. Unmeasured factors
influencing cohort participation may bias our frailty esti-
mates. Cognitive impairment and depression, however, did
not affect the conclusions as indicated by the sensitivity
analysis on the mortality effects.
The non-specific nature of the FI has led to some criti-
cism but it reflects the non-specific and complex nature of
ageing itself [27]. Despite being represented by a single def-
icit, consequences of serious health conditions are reflected
in additional deficits. In addition, the deficits used were
self-reported with the exception of mobility, eyesight, hear-
ing, and cognitive impairment, which were test-based.
There is some evidence to suggest that a FI is more robust
with the inclusion of both test-based and self-reported defi-
cits [28].
Large sample sizes in the CFAS studies allow for
increased power to detect differences, and the MICE meth-
od preserves this statistical power by using all available data
and producing less biased estimates [29]. A study by McCaul
et al. [30], found that imputed frailty estimates were ~10%
higher than complete-case analysis estimates. Similarly, we
found that the adjusted frailty effect on mortality was higher
in the imputed analysis than the complete-case analysis. This
indicates that missingness of frailty may be associated with
higher mortality levels which is consistent with our under-
standing of missingness in longitudinal studies. However,
this difference was not significant in this study.
Findings
Our findings agree with previous reports that women have
higher frailty scores but lower mortality than men [22, 31,
32, 33]. This may be explained by the concepts of male ‘fit-
ness-frailty pleiotropy’ and female ‘fertility-frailty pleiotropy’
which result in lower physiological reserves in men. It is
hypothesised that the threshold for system failure at old age
in men is low as a result of better physiological functioning
during youth, but in women this threshold has increased by
limiting childbearing [34]. Similar to most studies [9, 35, 36],
the maximum FI was ~0.7 suggesting that surviving beyond
that is unlikely. Differences in submaximal and maximal lim-
its have been reported, supporting the theory that women
have higher physiological reserves than men [20, 36–38].
Despite a decrease in the absolute 2-year mortality risk
for a given level of frailty, the RR of mortality has remained
unchanged in CFAS II. These findings contrast with a
Swedish study that compared 70-year olds born in 1900
with those born in 1930; in the latter, the long-term lethality
of frailty declined [23]. This could reflect period or country
effects, and particularly differences in healthcare systems or
a longer interval between cohorts. Overall, the estimate of
the association of frailty with mortality is consistent with
those from other cohorts [8], with an OR of ~1.6 for every
0.1 increment in the FI. Higher frailty indices in CFAS II
were mostly attributable to increases in the proportion of
those with disabilities and morbidities such as diabetes,
hypertension, meningitis, arthritis and thyroid problems
(Appendix A in the Supplementary data, available at Age
and Ageing online). Changes in practice that occurred
between the two cohorts such as the Quality and Outcomes
Framework for primary care introduced in 2004 may have
led to an increase in the reporting of conditions such as dia-
betes and hypertension, particularly at milder stages. Frailty
in the CFAS I population may have been relatively underes-
timated, partly explaining the observed decrease in absolute
mortality, despite the apparent increase in frailty. It may also
be that only conditions with an early onset have increased
in prevalence whereas those closer to death have decreased
or remained the same. Moreover, a substantial proportion
of the variability in mortality does not seem to be explained
by frailty, sex, age or cohort. Other factors such as sociode-
mographic and behavioural determinants may be influen-
cing frailty. A model adjusting for such factors may
improve prediction of both frailty and mortality.
Conclusions
Our results, from two similar population-based studies car-
ried out 20 years apart, reveal that despite lower mortality
in recent years, older populations have a higher FI and the
relationship of frailty with mortality is essentially unchanged
for the two generational cohorts. It is likely that changes in
reporting and diagnostic practice have increased the preva-
lence of lesser degrees of frailty, but despite this the rela-
tionship between frailty and mortality has remained stable
over two decades. This has implications for both policy
planning and clinical practice. Although the stable frailty–
mortality relationship might reflect when and where our
study was done, it is worth considering why, unlike the
Swedish study, the RR for mortality in relation to frailty did
not decline. One possible explanation is that an interven-
tional service response sufficient to meet needs is required
[39], something that emerging experience with the eFI [15]
along with further investigation in contemporary cohorts
will be able to clarify.
Key points
• The FI of an ageing population allows relationships
between mortality and a unified measure of health to be
examined.
• A 12.3% relative decrease in mortality and an 8.4% rela-
tive increase in frailty were observed in two cohorts set 20
years apart.
• The relationship between frailty and mortality has not
changed, despite changes in occurrence and death rates
over time.
• This complex relationship may be accounted for by a
reduction of mortality at lower levels of frailty and
improved diagnosis.
• A measure of frailty is a stable tool through time that can
be used to indicate individuals at higher risk of mortality.
Is frailty a stable predictor of mortality across time? Evidence from CFAS
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Supplementary Data
Supplementary data mentioned in the text are available to
subscribers in Age and Ageing online.
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